Literature DB >> 28423237

Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model.

Jacek Bil1, Robert J Gil1,2, Tomasz Pawlowski1, Krzysztof P Milewski3.   

Abstract

AIMS: The optimal treatment strategy for coronary bifurcation lesions is still unknown. The aim of the study was to assess applicability of the new cobalt-chromium version of the sirolimus-eluting dedicated bifurcation BiOSS® LIM C stent in comparison with regular sirolimus-eluting Orsiro®  stent in a porcine coronary model.
METHODS: A total of 13 BiOSS® LIM C stents and 6 Orsiro® stents were implanted in normal nonatherosclerotic porcine straight coronary arteries of six animals using 1.2:1.0 stent-to-artery ratio. Stent geometry and morphology were evaluated by Faxitron imaging. Vascular response was assessed by quantitative coronary angiography (QCA), optical coherence tomography (OCT), and histological analyses.
RESULTS: OCT performed at 28 days confirmed that all stents were patent with no signs of thrombus. In morphometric analysis, no differences between groups regarding stent diameter (P=.141), neointima area (P=.247), % area stenosis (P=.293), or % diameter stenosis (P=.069) were observed. Also, no significant differences were noted between groups regarding their histopathology scores. The injury and inflammation scores were low (mean grade<1) in all groups.
CONCLUSIONS: The novel BiOSS® LIM C stent demonstrates good short-term vascular effects in a porcine coronary bifurcation model which are comparable with Orsiro® stents.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Dedicated bifurcation stent; Sirolimus-eluting stent

Mesh:

Substances:

Year:  2017        PMID: 28423237     DOI: 10.1111/1755-5922.12267

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  3 in total

1.  Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent.

Authors:  Robert J Gil; Tomasz Pawłowski; Jacek Legutko; Maciej Lesiak; Adam Witkowski; Mariusz Gąsior; Adam Kern; Jacek Bil
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

2.  Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II.

Authors:  Jacek Bil; Robert J Gil; Adam Kern; Luis A Inigo-Garcia; Radoslaw Formuszewicz; Slawomir Dobrzycki
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-09-21       Impact factor: 1.426

3.  Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.

Authors:  Robert J Gil; Jacek Bil; Adam Kern; Luis A Iñigo-Garcia; Radoslaw Formuszewicz; Slawomir Dobrzycki; Dobrin Vassilev; Roxana Mehran
Journal:  Cardiovasc Ther       Date:  2020-01-21       Impact factor: 3.023

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.